CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia

Giovanni D'Arena, Candida Vitale, Giovanni Rossi, Marta Coscia, Paola Omede, Fiorella D'Auria, Teodora Statuto, Luciana Valvano, Stefania Ciolli, Milena Gilestro, Stefano Molica, Silvia Bellesi, Giuseppe Topini, Valentina Panichi, Francesco Autore, Idanna Innocenti, Pellegrino Musto, Silvia Deaglio, Luca Laurenti, Luigi Del Vecchio

Research output: Contribution to journalArticle

Abstract

CD200, a transmembrane type la glycoprotein belonging to the immunoglobulin super-family, has been shown to have a differential expression in B-cell neoplasms. Here, we retrospectively assessed the diagnostic relevance of CD200 on 427 patients with B-cell chronic neoplasms in leukemic phase (median age, 69 y; range, 35-97 y). The final diagnosis based on the investigator's assessment was chronic lymphocytic leukaemia (CLL) in 75% of cases and non-CLL in 25% of cases. Sensitivity and specificity for the diagnosis of CLL (vs non-CLL) were calculated for the following markers: CD200, CD5, CD22, CD23, CD79b, FMC7, and SmIg. CD23 was the only marker without a statistically significant difference between the investigator assessment and the flowcytometric analysis. The other markers were unable-when individually evaluated-to discriminate between CLL and non-CLL, requiring the integration into a scoring system. The modified score no. 1 (addition of CD200) showed superimposable sensitivity and specificity compared with the Matutes score. The substitution of CD79b (modified score no. 2), surface membrane immunoglobulins (Smig) (modified score no. 3), and CD79b and FMC7 (modified score no. 4) with CD200 showed that only the modified score no. 4 had both higher sensitivity and higher specificity compared with standard Matutes score. In conclusion, this work defines a simplified score, compared with the classical Matutes score, for the differential diagnosis of chronic B-cell leukaemia-which only requires 4 markers instead of 5 (CD5, CD23, CD200, and SmIg).
Original languageEnglish
Pages (from-to)543-546
Number of pages4
JournalHematological Oncology
Volume36
Issue number3
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Lymphoid Leukemia
Sensitivity and Specificity
B-Lymphocytes
Research Personnel
B-Cell Antigen Receptors
Immunoglobulins
Neoplasms
Glycoproteins
Differential Diagnosis
Membranes

Keywords

  • CD200
  • chronic lymphocytic leukaemia
  • diagnosis
  • flow cytometry
  • score

Cite this

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. / D'Arena, Giovanni; Vitale, Candida; Rossi, Giovanni; Coscia, Marta; Omede, Paola; D'Auria, Fiorella; Statuto, Teodora; Valvano, Luciana; Ciolli, Stefania; Gilestro, Milena; Molica, Stefano; Bellesi, Silvia; Topini, Giuseppe; Panichi, Valentina; Autore, Francesco; Innocenti, Idanna; Musto, Pellegrino; Deaglio, Silvia; Laurenti, Luca; Del Vecchio, Luigi.

In: Hematological Oncology, Vol. 36, No. 3, 01.08.2018, p. 543-546.

Research output: Contribution to journalArticle

D'Arena, G, Vitale, C, Rossi, G, Coscia, M, Omede, P, D'Auria, F, Statuto, T, Valvano, L, Ciolli, S, Gilestro, M, Molica, S, Bellesi, S, Topini, G, Panichi, V, Autore, F, Innocenti, I, Musto, P, Deaglio, S, Laurenti, L & Del Vecchio, L 2018, 'CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia', Hematological Oncology, vol. 36, no. 3, pp. 543-546. https://doi.org/10.1002/hon.2510
D'Arena, Giovanni ; Vitale, Candida ; Rossi, Giovanni ; Coscia, Marta ; Omede, Paola ; D'Auria, Fiorella ; Statuto, Teodora ; Valvano, Luciana ; Ciolli, Stefania ; Gilestro, Milena ; Molica, Stefano ; Bellesi, Silvia ; Topini, Giuseppe ; Panichi, Valentina ; Autore, Francesco ; Innocenti, Idanna ; Musto, Pellegrino ; Deaglio, Silvia ; Laurenti, Luca ; Del Vecchio, Luigi. / CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. In: Hematological Oncology. 2018 ; Vol. 36, No. 3. pp. 543-546.
@article{8275ec95b85d47818c464f804b83c37b,
title = "CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia",
abstract = "CD200, a transmembrane type la glycoprotein belonging to the immunoglobulin super-family, has been shown to have a differential expression in B-cell neoplasms. Here, we retrospectively assessed the diagnostic relevance of CD200 on 427 patients with B-cell chronic neoplasms in leukemic phase (median age, 69 y; range, 35-97 y). The final diagnosis based on the investigator's assessment was chronic lymphocytic leukaemia (CLL) in 75{\%} of cases and non-CLL in 25{\%} of cases. Sensitivity and specificity for the diagnosis of CLL (vs non-CLL) were calculated for the following markers: CD200, CD5, CD22, CD23, CD79b, FMC7, and SmIg. CD23 was the only marker without a statistically significant difference between the investigator assessment and the flowcytometric analysis. The other markers were unable-when individually evaluated-to discriminate between CLL and non-CLL, requiring the integration into a scoring system. The modified score no. 1 (addition of CD200) showed superimposable sensitivity and specificity compared with the Matutes score. The substitution of CD79b (modified score no. 2), surface membrane immunoglobulins (Smig) (modified score no. 3), and CD79b and FMC7 (modified score no. 4) with CD200 showed that only the modified score no. 4 had both higher sensitivity and higher specificity compared with standard Matutes score. In conclusion, this work defines a simplified score, compared with the classical Matutes score, for the differential diagnosis of chronic B-cell leukaemia-which only requires 4 markers instead of 5 (CD5, CD23, CD200, and SmIg).",
keywords = "CD200, chronic lymphocytic leukaemia, diagnosis, flow cytometry, score",
author = "Giovanni D'Arena and Candida Vitale and Giovanni Rossi and Marta Coscia and Paola Omede and Fiorella D'Auria and Teodora Statuto and Luciana Valvano and Stefania Ciolli and Milena Gilestro and Stefano Molica and Silvia Bellesi and Giuseppe Topini and Valentina Panichi and Francesco Autore and Idanna Innocenti and Pellegrino Musto and Silvia Deaglio and Luca Laurenti and {Del Vecchio}, Luigi",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/hon.2510",
language = "English",
volume = "36",
pages = "543--546",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "3",

}

TY - JOUR

T1 - CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia

AU - D'Arena, Giovanni

AU - Vitale, Candida

AU - Rossi, Giovanni

AU - Coscia, Marta

AU - Omede, Paola

AU - D'Auria, Fiorella

AU - Statuto, Teodora

AU - Valvano, Luciana

AU - Ciolli, Stefania

AU - Gilestro, Milena

AU - Molica, Stefano

AU - Bellesi, Silvia

AU - Topini, Giuseppe

AU - Panichi, Valentina

AU - Autore, Francesco

AU - Innocenti, Idanna

AU - Musto, Pellegrino

AU - Deaglio, Silvia

AU - Laurenti, Luca

AU - Del Vecchio, Luigi

PY - 2018/8/1

Y1 - 2018/8/1

N2 - CD200, a transmembrane type la glycoprotein belonging to the immunoglobulin super-family, has been shown to have a differential expression in B-cell neoplasms. Here, we retrospectively assessed the diagnostic relevance of CD200 on 427 patients with B-cell chronic neoplasms in leukemic phase (median age, 69 y; range, 35-97 y). The final diagnosis based on the investigator's assessment was chronic lymphocytic leukaemia (CLL) in 75% of cases and non-CLL in 25% of cases. Sensitivity and specificity for the diagnosis of CLL (vs non-CLL) were calculated for the following markers: CD200, CD5, CD22, CD23, CD79b, FMC7, and SmIg. CD23 was the only marker without a statistically significant difference between the investigator assessment and the flowcytometric analysis. The other markers were unable-when individually evaluated-to discriminate between CLL and non-CLL, requiring the integration into a scoring system. The modified score no. 1 (addition of CD200) showed superimposable sensitivity and specificity compared with the Matutes score. The substitution of CD79b (modified score no. 2), surface membrane immunoglobulins (Smig) (modified score no. 3), and CD79b and FMC7 (modified score no. 4) with CD200 showed that only the modified score no. 4 had both higher sensitivity and higher specificity compared with standard Matutes score. In conclusion, this work defines a simplified score, compared with the classical Matutes score, for the differential diagnosis of chronic B-cell leukaemia-which only requires 4 markers instead of 5 (CD5, CD23, CD200, and SmIg).

AB - CD200, a transmembrane type la glycoprotein belonging to the immunoglobulin super-family, has been shown to have a differential expression in B-cell neoplasms. Here, we retrospectively assessed the diagnostic relevance of CD200 on 427 patients with B-cell chronic neoplasms in leukemic phase (median age, 69 y; range, 35-97 y). The final diagnosis based on the investigator's assessment was chronic lymphocytic leukaemia (CLL) in 75% of cases and non-CLL in 25% of cases. Sensitivity and specificity for the diagnosis of CLL (vs non-CLL) were calculated for the following markers: CD200, CD5, CD22, CD23, CD79b, FMC7, and SmIg. CD23 was the only marker without a statistically significant difference between the investigator assessment and the flowcytometric analysis. The other markers were unable-when individually evaluated-to discriminate between CLL and non-CLL, requiring the integration into a scoring system. The modified score no. 1 (addition of CD200) showed superimposable sensitivity and specificity compared with the Matutes score. The substitution of CD79b (modified score no. 2), surface membrane immunoglobulins (Smig) (modified score no. 3), and CD79b and FMC7 (modified score no. 4) with CD200 showed that only the modified score no. 4 had both higher sensitivity and higher specificity compared with standard Matutes score. In conclusion, this work defines a simplified score, compared with the classical Matutes score, for the differential diagnosis of chronic B-cell leukaemia-which only requires 4 markers instead of 5 (CD5, CD23, CD200, and SmIg).

KW - CD200

KW - chronic lymphocytic leukaemia

KW - diagnosis

KW - flow cytometry

KW - score

U2 - 10.1002/hon.2510

DO - 10.1002/hon.2510

M3 - Article

VL - 36

SP - 543

EP - 546

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -